Novo Nordisk en las noticias
Soluciones sanitarias para la diabetes
Tamtam encontró 20 artículos recientes sobre Novo Nordisk.
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
- Aktien er nede med 22 pct. i år: Her er analytikernes dom over Novo-aktien
- Novo Nordisk introduces new diabetes treatment option in Thailand
- Hackers had access to Novo Nordisk systems for at least 47 days
- Novo goes on deal spree amid semaglutide patent expiries
- QMs samarbejde med Novo Nordisk og Qpurpose
- Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
- Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
- Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
- Novo Nordisk (NVO) Pulls Back Sharply, Is It A Bargain?
- Novo flags FDA hemophilia review extension tied to manufacturing site corrections
- FDA delays decision on Novo's hemophilia drug
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S : JP Morgan is Neutral
- Novo Looks Beyond GLP-1s as Competition Intensifies
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
- Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
- Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- Novo Nordisk (NVO) Stock Looks Reasonable Given Uncertain Long Term Earnings
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Novo Nordisk?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares